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ABSTRACT We conducted a post hoc analysis to assess the potential impact of GAP (gender, age,
physiology) stage on the treatment effect of nintedanib in patients with idiopathic pulmonary fibrosis.
Outcomes were compared in patients at GAP stage I versus II/III at baseline in the INPULSIS® trials.
At baseline, 500 patients were at GAP stage I (nintedanib 304, placebo 196), 489 were at GAP stage II
(nintedanib 296, placebo 193) and 71 were at GAP stage III (nintedanib 38, placebo 33). In nintedanib-
treated patients, the annual rate of decline in forced vital capacity (FVC) was similar in patients at GAP
stage I and GAP stage II/III at baseline (−110.1 and −116.6 mL·year−1, respectively), and in both
subgroups was lower than in placebo-treated patients (−218.5 and −227.6 mL·year−1, respectively)
(treatment-by-time-by-subgroup interaction p=0.92). In the nintedanib group, the number of deaths was
43.8% of those predicted based on GAP stage (35 versus 79.9). In the placebo group, the number of deaths
was 59.8% of those predicted based on GAP stage (33 versus 55.2).
In conclusion, data from the INPULSIS® trials suggest that nintedanib has a similar beneficial effect on
the rate of FVC decline in patients at GAP stage I versus II/III at baseline.
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ORIGINAL ARTICLE
INTERSTITIAL LUNG DISEASE
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease (ILD) that is
characterised by loss of lung function, reduced quality of life, acute exacerbations and high mortality [1].
The median survival of patients with IPF is ∼3 years from the time of diagnosis [2].
Baseline and changes from baseline in individual physiological variables, including forced vital capacity
(FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO), have been shown to be predictors
of mortality in patients with IPF [3–6]. Several composite risk prediction scores have been developed with
the aim of more accurately predicting mortality. The GAP (gender, age, physiology) index and staging
system was designed to be a quick and simple method for estimating mortality risk [7]. The GAP index is
based on four commonly measured variables (sex, age, FVC % predicted, DLCO % pred) and was validated
in three cohorts of patients in a real-world setting [7].
Nintedanib is a tyrosine kinase inhibitor that slows disease progression by reducing the rate of decline in
lung function in patients with IPF [8, 9]. Nintedanib has an acceptable safety profile and is approved for
the treatment of IPF in many countries and regions, including the USA, Canada, Europe and Japan.
Nintedanib has consistent effects in multiple subgroups of patients with IPF [10–14]; however, it is
unknown whether the impact of nintedanib is similar across GAP stages, or whether a staging system
could facilitate future clinical trials by enriching study cohorts for patients at greater risk for outcomes of
interest. The objective of this study was to assess the potential impact of GAP stage on the benefits,
tolerability and safety of nintedanib in patients with IPF.
Methods
Study design
The INPULSIS® trials were two replicate, randomised, double-blind, phase III trials that compared the
effects of nintedanib 150 mg twice daily with placebo over 52 weeks of treatment in patients with IPF [8].
The studies included 1066 patients from 205 sites in 24 countries, of whom 1061 received at least one dose
of study drug, with a 3:2 randomisation of nintedanib to placebo. To be eligible for these trials, patients
had to be aged ⩾40 years, have an FVC ⩾50% pred and have a DLCO 30–79% pred. The primary
end-point in both trials was the annual rate of decline in FVC (mL·year−1). Key secondary end-points
were the time to first investigator-reported acute exacerbation over 52 weeks and change from baseline in
St George’s Respiratory Questionnaire (SGRQ) total score, a measure of health-related quality of life, over
52 weeks. Details of the methodology used in the INPULSIS® trials have been published [8, 15].
Study measurements
FVC was measured using standardised equipment according to established recommendations [16] at
baseline, at weeks 2, 4, 6, 12, 24, 36 and 52, and at a follow-up visit 4 weeks later. Patients who
prematurely discontinued trial medication were asked to complete all visits as planned. DLCO (corrected
for haemoglobin) was measured at baseline and at weeks 24 and 52 using the investigator’s own
equipment and in compliance with American Thoracic Society/European Respiratory Society guidelines on
single-breath determination of carbon monoxide uptake [17].
Acute exacerbations of IPF were defined as events meeting all of the following criteria: unexplained
worsening or development of dyspnoea within 30 days; new diffuse pulmonary infiltrates on chest
radiography and/or high-resolution computed tomography or the development of parenchymal
abnormalities with no pneumothorax or pleural effusion (new ground glass opacities) since the preceding
visit; and exclusion of any known causes of acute worsening in accordance with routine clinical practice
and microbiological studies. Acute exacerbations that occurred up to 52 weeks plus a 1-week margin after
randomisation were included in these analyses.
The SGRQ was measured at baseline and at weeks 6, 12, 24 and 52. The SGRQ is a patient-reported
respiratory disease-specific quality-of-life questionnaire that includes three domains (symptoms, activity,
impact) [18]. Scores for each domain and the total score are weighted so that they range from 0 to 100,
with higher scores indicating worse health-related quality of life. The minimally important difference in
patients with IPF has been estimated to be between 4 and 10 points [19, 20].
Safety was measured by clinical and laboratory evaluation and the recording of adverse events from the
first dose of study drug until 28 days after the last dose of study drug.
GAP index and stage
In the GAP index and staging system, points are assigned to each variable (sex, age, FVC, DLCO) to obtain
a total point score (GAP index) ranging from 0 to 8 [7]. The GAP index is used to classify patients as at
GAP stage I (0–3 points), GAP stage II (4–5 points) or GAP stage III (6–8 points). Based on data from
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228 patients in a derivation cohort (followed for a median 1.7 years) and 330 patients in a validation
cohort (followed for a median 2.4 years), model-predicted estimates of mortality at 1 year were 5.6%,
16.2% and 39.2% for patients at GAP stages I, II and III, respectively [7]. In this analysis, the GAP index
and stage were calculated for all patients in whom the relevant baseline assessments were available.
Statistical analysis
Post hoc subgroup analyses were conducted using pooled data from the two INPULSIS® trials. Patients
were stratified by baseline GAP stage. Analyses were conducted on subgroups of patients by individual
GAP stage (I, II, III) and by GAP stage I versus II/III, given the small number of patients at GAP stage III.
The primary end-point (annual rate of decline in FVC) and key secondary end-points (time to first
investigator-reported acute exacerbation and change from baseline in SGRQ total score) were analysed
using the original statistical approach within each GAP stage subgroup. For the primary end-point, the
subgroup and the interaction terms treatment-by-subgroup, time-by-subgroup and treatment-by-time-by-
subgroup were included in the model. For the key secondary end-points, the subgroup and a treatment-
by-subgroup interaction term were included in the model. Time to disease progression (defined as
absolute FVC decline ⩾5% pred or death, or absolute FVC decline ⩾10% pred or death) over 52 weeks
was assessed using a Cox’s regression model with the subgroup and an interaction term treatment-by-
subgroup included. For all the subgroup analyses, the presence of a statistically significant interaction term
could indicate a difference in the impact of nintedanib versus placebo across GAP stages. Safety analyses
were descriptive.
Results
Patients
At baseline, GAP index and stage could be calculated in 1060 patients treated with at least one dose of
study drug (supplementary table S1). Data on baseline DLCO were not available for one patient treated
with placebo. The study population comprised 500 patients at GAP stage I (nintedanib 304, placebo 196),
489 at GAP stage II (nintedanib 296, placebo 193), and 71 at GAP stage III (nintedanib 38, placebo 33).
Baseline characteristics were generally balanced between the nintedanib and placebo arms within the GAP
stage I and GAP stage II/III subgroups (table 1). Patients at GAP stage II/III were older, more likely to be
male and had lower FVC and DLCO % pred compared with patients at GAP stage I. Baseline FVC and
DLCO % pred for each GAP index and stage are summarised in supplementary table S2.
The planned observation time was completed in 89.6% of patients at GAP stage I and 77.9% of patients at
GAP stage II/III. In patients at GAP stage I, mean±SD duration of exposure to study medication was
10.5±3.3 months and 11.3±2.1 months in the nintedanib and placebo groups, respectively. In patients at
TABLE 1 Baseline characteristics stratified by baseline GAP (gender, age, physiology) stage
GAP stage I GAP stage II/III
Nintedanib Placebo Nintedanib Placebo
Subjects 304 196 334 226
Age years 62.9±8.1 63.1±8.3 70.0±6.6 70.3±5.8
Male 208 (68.4) 132 (67.3) 299 (89.5) 202 (89.4)
Race
White 173 (56.9) 110 (56.1) 187 (56.0) 137 (60.6)
Asian 94 (30.9) 60 (30.6) 100 (29.9) 68 (30.1)
Black 0 (0.0) 0 (0.0) 2 (0.6) 0 (0.0)
Missing# 37 (12.2) 26 (13.3) 45 (13.5) 21 (9.3)
Former or current smoker 209 (68.8) 130 (66.3) 255 (76.3) 171 (75.7)
FVC mL 2883±823 2957±911 2559±656 2537±645
FVC % predicted 85.8±17.3 87.4±18.9 74.2±16.0 72.3±14.2
FEV1/FVC ratio 81.4±5.6 81.1±6.1 81.9±6.1 82.2±5.8
DLCO % predicted 54.0±13.8 53.5±14.1 41.4±10.0 41.3±9.7
SGRQ total score¶ 36.2±19.7 38.2±19.3 42.6±18.2 40.7±17.8
Data are presented as n, mean±SD or n (%). FVC: forced vital capacity; FEV1: forced expiratory volume in
1 s; DLCO: diffusing capacity of the lung for carbon monoxide; SGRQ: St George’s Respiratory
Questionnaire. #: in France, regulations did not permit the collection of data on race; ¶: n=299 for
nintedanib and n=194 for placebo in GAP stage I subgroup; n=325 for nintedanib and n=224 for placebo in
GAP stage II/III subgroup.
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GAP stage II/III, mean±SD duration of exposure to study medication was 10.1±3.4 months and
10.4±3.3 months in the nintedanib and placebo groups, respectively.
FVC
In nintedanib-treated patients, the annual rate of decline in FVC was similar in patients at GAP stage I
and GAP stage II/III at baseline (−110.1 mL·year−1 and −116.6 mL·year−1, respectively) and in both
subgroups was lower than in placebo-treated patients (−218.5 mL·year−1 and −227.6 mL·year−1,
respectively) (figure 1). The observed changes in FVC over time in each subgroup are shown in figure 2.
The treatment effect of nintedanib on reducing the annual rate of decline in FVC was consistent between
patients at GAP stage I and GAP stage II/III at baseline (treatment-by-time-by-subgroup interaction
p=0.92). The benefit of nintedanib on FVC in these GAP stage subgroups was consistent with the
treatment effect in the overall population (109.9 mL·year−1, 95% CI 75.9–144.0 mL·year−1; p<0.0001) [8].
In the analysis of the annual rate of decline in FVC in patients at GAP stage I, II and III at baseline, the
effect of nintedanib was numerically greater in patients at GAP stage III (treatment-by-time-by-subgroup
interaction p=0.10) (supplementary figure S1).
Disease progression and mortality
The treatment effect of nintedanib on disease progression, measured by time to absolute FVC decline ⩾5%
pred or death, or absolute FVC decline ⩾10% pred or death, over 52 weeks, was consistent across
subgroups of patients at GAP stage I and II/III at baseline (table 2) and across subgroups of patients at
GAP stages I, II and III (supplementary table S3).
Based on the number of deaths observed versus the number of deaths predicted based on GAP stage, nintedanib
was associated with a relative reduction in the risk of mortality of 26.7% compared with placebo (table 3).
Acute exacerbation
The proportion of patients who had an acute exacerbation was higher in patients at GAP stage II/III than
at GAP stage I (8.4% versus 3.0%). In patients at GAP stage I, the proportion of patients with one or more
acute exacerbations was 1.6% in the nintedanib group and 5.1% in the placebo group. In patients at GAP
stage II/III, the proportion of patients with one or more acute exacerbations was 7.8% in the nintedanib
group and 9.3% in the placebo group. In the overall pooled population, there was a numerical reduction in
the risk of having a first acute exacerbation with nintedanib versus placebo (hazard ratio (HR) 0.64, 95%
CI 0.39–1.05; p=0.08) [8]. Nintedanib had a numerically greater effect on time to first acute exacerbation
in patients at GAP stage I (HR 0.32, 95% CI 0.11–0.93) than GAP stage II/III (HR 0.82, 95% CI
0.46–1.47); however, the treatment-by-subgroup interaction was not significant (p=0.14; figure 3). The
effect of nintedanib on time to first acute exacerbation across subgroups of patients at GAP stage I, II and
III is presented in supplementary table S4.
–50
0
–218.5
Treatment-by-time-by-
subgroup interaction
p=0.92
n=196
–100
–150
–200
–250
–300
–350
–400
–450
A
d
ju
s
te
d
 a
n
n
u
a
l 
ra
te
 ±
S
E
 o
f 
d
e
c
li
n
e
 i
n
 
F
V
C
 m
L
·y
e
a
r–
1
Δ108.4 mL
(95% CI 58.7–158.0 mL)
Δ111.1 mL
(95% CI 63.8–158.3 mL)
–110.1
n=304
Nintedanib
GAP stage I
n=226n=334
GAP stage II/III
–227.6
–116.6
Placebo
FIGURE 1 Annual rate of decline in forced vital capacity (FVC) by baseline GAP (gender, age, physiology)
stage.
https://doi.org/10.1183/23120541.00127-2018 4
INTERSTITIAL LUNG DISEASE | C.J. RYERSON ET AL.
Health-related quality of life
Patients had worse SGRQ total scores at baseline with increasing GAP stage (37.0, 40.5 and 50.8 for
patients at GAP stage I, II and III, respectively). There was no significant difference between the
nintedanib and placebo groups in change from baseline in SGRQ total score at week 52 in the overall
population (−1.43, 95% CI −3.09–0.23; p=0.09) [8].
The treatment effect of nintedanib on change from baseline in SGRQ total score seemed to be more
pronounced in patients at GAP stage II/III versus patients at GAP stage I at baseline. The difference in
adjusted mean change from baseline in SGRQ total score at week 52 between nintedanib and placebo was
−2.67 (95% CI −5.07–−0.27) and 0.09 (95% CI −2.20–2.38) for patients at GAP stage II/III and GAP
stage I, respectively (treatment-by-subgroup interaction p=0.06; figure 4). Similarly, there was a more
pronounced treatment effect in the activity and impact domains of the SGRQ across patients at GAP
stages I and II/III (p=0.09 and p=0.12, respectively), but not for the symptoms domain (p=0.90)
(supplementary table S5). Across patients at GAP stage I, II and III at baseline, the treatment effect was
numerically greater with increasing GAP stage; however, the treatment-by-subgroup interaction was not
significant (p=0.21; supplementary figure S2).
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FIGURE 2 Mean observed change from baseline in forced vital capacity (FVC) by baseline GAP (gender, age,
physiology) stage.
TABLE 2 Proportions of patients with disease progression over 52 weeks and hazard ratio for time to first event by baseline
GAP (gender, age, physiology) stage
GAP stage I Hazard ratio
(95% CI)
GAP stage II/III Hazard ratio
(95% CI)
Treatment-by-subgroup
interaction p-valueNintedanib Placebo Nintedanib Placebo
Subjects n 304 196 334 226
Absolute decline in FVC ⩾10%
predicted or death
75 (24.7) 78 (39.8) 0.59 (0.43–0.81) 98 (29.3) 97 (42.9) 0.60 (0.45–0.79) 0.84
Criterion reached first
Absolute decline in
FVC ⩾10% predicted
69 (22.7) 75 (38.3) 79 (23.7) 78 (34.5)
Death 6 (2.0) 3 (1.5) 19 (5.7) 19 (8.4)
Absolute decline in FVC ⩾5%
predicted or death
156 (51.3) 142 (72.4) 0.58 (0.46–0.73) 174 (52.1) 160 (70.8) 0.63 (0.51–0.78) 0.55
Criterion reached first
Absolute decline in FVC ⩾5%
predicted
154 (50.7) 141 (71.9) 163 (48.8) 150 (66.4)
Death 2 (0.7) 1 (0.5) 11 (3.3) 10 (4.4)
Data are presented as n or n (%), unless otherwise stated. FVC: forced vital capacity.
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Safety and tolerability
Data on adverse events are summarised in table 4. In patients at GAP stage I, patients who were treated
with nintedanib were more likely to discontinue study drug prematurely than patients treated with
placebo, with similar rates of discontinuation in nintedanib- and placebo-treated patients in the GAP stage
II/III subgroups. Diarrhoea was the most frequent adverse event that resulted in permanent treatment
discontinuation in patients treated with nintedanib. Serious and fatal adverse events within each subgroup
by GAP stage are summarised in supplementary table S6.
Discussion
This post hoc subgroup analysis of pooled data from the INPULSIS® trials suggested that nintedanib had a
similar benefit on the rate of FVC decline across patient subgroups stratified by baseline GAP stage I
TABLE 3 Observed versus predicted deaths based on baseline GAP (gender, age, physiology)
stage
GAP stage Observed deaths as a proportion of
predicted deaths %I II III Total
Nintedanib subjects 304 296 38 638 43.8
Predicted deaths 17.0 48.0 14.9 79.9
Observed deaths 9 23 3 35
Placebo subjects 196 193 33 422 59.8
Predicted deaths 11.0 31.3 12.9 55.2
Observed deaths 7 19 7 33
Data are presented as n, unless otherwise stated.
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TABLE 4 Tolerability and safety of nintedanib in subgroups by baseline GAP (gender, age,
physiology) stage
GAP stage I GAP stage II/III
Nintedanib Placebo Nintedanib Placebo
Subjects n 304 196 334 226
Adverse event(s) 289 (95.1) 177 (90.3) 320 (95.8) 201 (88.9)
Most frequent adverse event(s)#
Diarrhoea 188 (61.8) 34 (17.3) 210 (62.9) 44 (19.5)
Nausea 79 (26.0) 13 (6.6) 77 (23.1) 15 (6.6)
Nasopharyngitis 46 (15.1) 27 (13.8) 41 (12.3) 41 (18.1)
Cough 43 (14.1) 26 (13.3) 42 (12.6) 31 (13.7)
Vomiting 42 (13.8) 5 (2.6) 32 (9.6) 6 (2.7)
Decreased appetite 23 (7.6) 7 (3.6) 45 (13.5) 17 (7.5)
Progression of IPF¶ 17 (5.6) 18 (9.2) 47 (14.1) 42 (18.6)
Weight decreased 26 (8.6) 6 (3.1) 36 (10.8) 9 (4.0)
Upper respiratory tract infection 23 (7.6) 21 (10.7) 35 (10.5) 21 (9.3)
Abdominal pain 32 (10.5) 5 (2.6) 24 (7.2) 5 (2.2)
Dyspnoea 18 (5.9) 23 (11.7) 31 (9.3) 25 (11.1)
Bronchitis 26 (8.6) 24 (12.2) 41 (12.3) 21 (9.3)
Serious adverse event(s)+ 60 (19.7) 45 (23.0) 134 (40.1) 81 (35.8)
Fatal adverse event(s) 8 (2.6) 6 (3.1) 29 (8.7) 25 (11.1)
Adverse event(s) leading to treatment discontinuation 48 (15.8) 16 (8.2) 75 (22.5) 39 (17.3)
Most frequent adverse event(s) leading to treatment
discontinuation§
Diarrhoea 10 (3.3) 1 (0.5) 18 (5.4) 0 (0.0)
Progression of IPF¶ 6 (3.1) 0 (0.0) 13 (3.9) 15 (6.6)
Nausea 7 (2.3) 0 (0.0) 6 (1.8) 0 (0.0)
Decreased appetite 2 (0.7) 1 (0.5) 7 (2.1) 0 (0.0)
Data are presented as n or n (%) of patients treated with at least one dose of study drug with one or more
such adverse event. IPF: idiopathic pulmonary fibrosis. #: adverse events reported in >10% of patients in
any subgroup; ¶: corresponds to MedDRA (Medical Dictionary for Regulatory Activities) term “IPF”, which
included disease worsening and acute exacerbations of IPF; +: an event that resulted in death, was
immediately life-threatening, resulted in persistent or clinically significant disability or incapacity, required
or prolonged hospitalisation, was related to a congenital anomaly or birth defect or was deemed serious
for any other reason; §: adverse events leading to treatment discontinuation in >2% of patients in any
subgroup.
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versus II/III. These findings extend the results of previous studies that identified consistent benefits of
nintedanib across many subgroups of patients with IPF [10–14, 21].
The GAP stage was developed as a mortality risk prediction tool in IPF, and has been suggested as a
potential mechanism of cohort enrichment for mortality-focused clinical trials [7]. In the INPULSIS®
trials, fewer deaths occurred in both treatment groups than were predicted based on GAP stage at baseline,
suggesting that the patients enrolled in these trials had lower 1-year mortality than the general population
of patients with IPF. Based on the difference between observed and predicted deaths, nintedanib was
associated with a relative reduction in the risk of 1-year mortality of 26.7% versus placebo. Nintedanib
resulted in a similar reduction versus placebo in the risk of disease progression (defined as an absolute
FVC decline ⩾10% pred or death) across GAP stages. There was a numerically greater benefit of
nintedanib on disease progression in patients at GAP stage III than GAP stage I or II; however, the small
number of patients at GAP stage III limited the robustness of this analysis. Thus our results suggest that
GAP stage is unlikely to be a helpful mechanism for cohort enrichment for studies that are intended to
show physiological benefit of antifibrotic medications with similar effects to nintedanib. This finding is
consistent with recent data, suggesting that GAP stage does not predict physiologic disease progression in
IPF [22]. Conversely, acute exacerbations of IPF were more common in patients at GAP stage II/III than
at GAP stage I, consistent with previous studies reporting an increased risk of acute exacerbations in
patients with more advanced disease [10, 23, 24], suggesting that GAP stage may be helpful to enrich
cohorts for patients at higher risk of this outcome.
Pooled data from the INPULSIS® trials suggested that compared with placebo, nintedanib was associated
with a numerical benefit on health-related quality of life measured by SGRQ score and in the risk of
having a first investigator-reported acute exacerbation [8]. The current post hoc analysis suggests a greater
treatment effect of nintedanib on quality of life in patients at GAP stage II/III compared with GAP stage I.
The reasons for the potential difference across GAP stages are unclear. One possibility is that a similar rate
of decline in FVC may have greater impact on quality of life in patients with more advanced disease, and
thus the consistent effect of nintedanib on decline in FVC across GAP stages may have greater impact on
quality of life in patients with more advanced disease. Similarly, there was a trend toward benefit of
nintedanib on acute exacerbations of IPF in patients at GAP stage II/III compared with patients at GAP
stage I. Additional studies are needed to evaluate whether nintedanib can improve quality of life or prevent
acute exacerbations in specific patient subgroups.
The overall proportion of patients who had at least one adverse event was similar in patients at GAP stage I
and GAP stage II/III and in the nintedanib and placebo arms within each subgroup. However, in patients
at GAP stage I, the proportion of patients who prematurely discontinued study drug due to adverse events
was nearly two-fold higher with nintedanib than with placebo, while premature discontinuations were
similar with nintedanib and placebo in patients at GAP stage II/III. These findings suggest that patients
with mild disease may have been less willing to accept adverse events than patients with more advanced
disease. There are several potential explanations for this finding, including patient differences across GAP
stages that impact tolerability of adverse events, greater acceptance of adverse events in patients with more
advanced disease, and greater symptomatic benefit of preserving a given amount of lung function in
patients with more advanced disease. A higher medication discontinuation rate in patients at GAP stage I
may have implications for the design of clinical trials.
In summary, this post hoc analysis suggested that nintedanib has similar benefit on the rate of FVC decline
between patients at GAP stage I versus II/III, indicating that GAP stage is unlikely to be a helpful tool for
cohort enrichment in similarly designed clinical trials of pharmacotherapies for IPF. There were GAP
stage-specific differences of unknown relevance in quality of life, time to first acute exacerbation and rate
of discontinuation of nintedanib. This cohort included relatively few patients at GAP stage III and
additional studies would be required to validate these findings and extend these results to a broader
cohort.
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